The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing

C. S. Ambrose*, F. Dubovsky, T. Yi, R. B. Belshe, S. Ashkenazi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2-17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in children with asthma aged 6-17 years have been demonstrated. However, few data are available for children younger than 6 years of age with asthma or prior wheezing. Safety and efficacy data were collected for children aged 2-5 years with asthma or prior wheezing fromtwo randomized, multinational trials of LAIV and TIV (N01,940). Wheezing, lower respiratory illness, and hospitalization were not significantly increased among children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed among LAIV recipients (p

Original languageEnglish
Pages (from-to)2549-2557
Number of pages9
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume31
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Dive into the research topics of 'The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing'. Together they form a unique fingerprint.

Cite this